A study of malignant lymphomas in Iran, based on the updated Kiel classification

1991 ◽  
Vol 419 (6) ◽  
pp. 451-454
Author(s):  
H. Tabrizchi ◽  
R. K. Gupta ◽  
M. R. Rafii
Keyword(s):  
Malignant Lymphomas ◽  
Kiel Classification

Preliminary clinical findings on the Kiel classification of malignant Lymphomas

1976 ◽  
Vol 87 (3) ◽  
pp. 229-238 ◽  
Author(s):  
K. Musshoff ◽  
H. Schmidt-Vollmer ◽  
K. Lennert ◽  
W. Sandritter
Keyword(s):  
Clinical Findings ◽  
Malignant Lymphomas ◽  
Kiel Classification

Non-Hodgkin malignant lymphomas. Clinico-pathologic correlations with the Kiel classification

1978 ◽  
Vol 14 (5) ◽  
pp. 587-592 ◽  
Author(s):  
C. Meugé ◽  
B. Hoerni ◽  
A. De Mascarel ◽  
M. Durand ◽  
P. Richaud ◽  
...  
Keyword(s):  
Malignant Lymphomas ◽  
Kiel Classification

Prognostic Value of the Kiel Classification of Malignant Non-hodgkin's Lymphomas

1979 ◽  
Vol 65 (2) ◽  
pp. 207-213 ◽  
Author(s):  
Roberto Bettini ◽  
Giovanni Chelazzi
Keyword(s):  
Prognostic Value ◽  
Low Grade ◽  
High Grade ◽  
Malignant Lymphomas ◽  
Kiel Classification ◽  
Significant Difference ◽  
Grade Malignancy ◽  
Hodgkin's Lymphomas ◽  
High Grade Malignancy

The aim of the present research was to evaluate the prognostic value of the Kiel classification of malignant non-Hodgkin's lymphomas. For this purpose a series of 100 consecutive, previously untreated adults with advanced malignant non-Hodgkin's lymphomas was analyzed. The median age of the patients was 54 years; 61 patients were males. Although the number of the various groups considered was limited, a statistically significant difference (p < 0.001) was found in the median survival of patients with lymphomas of low-grade malignancy (lymphocytic, lymphoplasmacytoid, centrocytic, centroblastic-centrocytic lymphoma) and lymphomas of high-grade malignancy (centroblastic, lymphoblastic, immunoblastic lymphoma). A difference in survival (p < 0.001) was also observed among the patients with lymphocytic lymphoma and those with centroblastic-centrocytic lymphoma, whereas no significant difference in survival was found between the histological subtypes of high-grade malignant lymphomas. Our observations support the opinion that the Kiel classification is useful in clinical practice to distinguish the histological types with a better prognosis from those with a worse one; in addition this classification appears to be of conceptual value.

51Cr-Bleomycin, a New Oncophilic Radiopharmaceutical II. Scintigraphic Diagnosis of Malignant Neoplasms

1982 ◽  
Vol 21 (02) ◽  
pp. 68-71 ◽  
Author(s):  
D. Brykalski ◽  
T. Pertyński ◽  
Maria Rembelska ◽  
K. Durski ◽  
S. Fajndt ◽  
...  
Keyword(s):  
Gamma Camera ◽  
Malignant Neoplasms ◽  
Cervix Carcinoma ◽  
Malignant Lymphomas ◽  
Hodgkins Lymphoma ◽  
67Ga Citrate

51Cr-bleomycin was used for the scintigraphic detection of tumours and the assessment of the spread of the disease in 20 patients with various malignances: 7 with Hodgkins Lymphoma, 5 with other malignant lymphomas, 4 cases of cervix carcinoma and 4 other tumours. The scintigraphy was performed using a Toshiba GC 401 gamma camera coupled to an MDSI computer Trinary. Active foci were scored using a semiquantitative scale of 0 to 5. Results of these studies were compared with those of tests similarly carried out with 57Co-bleomycin (in 9 of the cases) and 67Ga-citrate (11 cases); they demonstrated that the properties of 51Cr-bleomycin for scintigraphic detection of neoplastic foci are similar to those of 57Co-bleomycin.

PREDICTIVE SIGNIFICANCE OF HIGH SERUM FERRITIN LEVELS IN THE DEBUT OF MALIGNANT LYMPHOMA

2020 ◽  
pp. 74-81
Author(s):  
Babaeva T.N. ◽  
Seregina O.B. ◽  
Pospelova T.I.
Keyword(s):  
Serum Ferritin ◽  
Serum Ferritin Level ◽  
Ferritin Level ◽  
Prognostic Significance ◽  
Average Concentration ◽  
High Serum ◽  
Control Group ◽  
Malignant Neoplasms ◽  
Significant Prognostic Factor ◽  
Malignant Lymphomas

At present, the serum ferritin level is not included in the list of prognostic factors; however, it is known that its increased serum level in patients with malignant neoplasms relates with the tumor burden, the degree of disease activity and correlates with a worse prognosis in patients with hematologic malignancies.The normalization of serum ferritin level during remission period confirms the involving of hyperferritinemia in mechanisms of tumor progression and may testify for clinical importance of measurement of serum ferritin level in patients, including those with malignant lymphomas. Objective:The aim of this study was to assess of the prognostic significance of high ferritin levels at the onset of the disease in patients with malignant lymphomas. Materials and methods:98 patients with malignant lymphomaswere enrolled in this study, including 72 patients (73.5%) with non-Hodgkins lymphomas (NHL) and 26 patients (26.5%) with Hodgkin’s lymphoma (HL). The increased serum ferritin level (more than 350 ng/ml) was found in 53 (54.2%) patients with malignant lymphomas at the onset of disease and its average concentration was 587,62±131,6 ng/ml (8.3 times higher values of control group, p<0.001).Also the positive statistical correlationsbetween increased ferritin level and increased level of LDH (r=0.47, p<0.001, n=98) and C-reactive protein (r=0.41, p<0.001, n=98) as well as the presence of B-symptomswere found. The median OS was significantly shorter in the group of patients with increased ferritin level (more than 350 ng/ml) at the onset of disease in comparison with group of patients with normal ferritin level, where the median OS was not reach during the observation period. Patients with increased ferritin level before starting chemotherapy also showed worse results of overall survival and increased mortality risk (OR 8.122; 95% CI, 1.764-37.396;р<0.05) compare with a group of patients with ferritin level ˂350 hg/ml at the onset of disease. Conclusion:These results make it possible to include lymphomas’s patients with increased ferritin level at the onset of disease in the group with poor prognosis and lower OS, while the increased ferritin level in patients without previous blood transfusions should be considered as a significant prognostic factor.

Benefit assessment of PET in malignant lymphomas. The IQWiG point of view

2010 ◽  
Vol 49 (1) ◽  
pp. 1-5 ◽  
Author(s):  
F. Scheibler ◽  
H. Raatz ◽  
K. Suter ◽  
I. Janßen ◽  
R. Grosselfinger ◽  
...  
Keyword(s):  
Point Of View ◽  
Benefit Assessment ◽  
Malignant Lymphomas

PD-1-PD-L1 immune-checkpoint blockade in malignant lymphomas

2017 ◽  
Vol 97 (2) ◽  
pp. 229-237 ◽  
Author(s):  
Yi Wang ◽  
Ling Wu ◽  
Chen Tian ◽  
Yizhuo Zhang
Keyword(s):  
Immune Checkpoint ◽  
Immune Checkpoint Blockade ◽  
Checkpoint Blockade ◽  
Malignant Lymphomas

Malignant lymphomas in children

1980 ◽  
Vol 15 (5) ◽  
pp. 707-708
Author(s):  
Randall W. Powell
Keyword(s):  
Malignant Lymphomas
Sign in / Sign up

Export Citation Format

Share Document